Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2023 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
June 06, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)

Conference hosted by the International Union of Biochemistry and Molecular Biology (IUBMB) to feature leading research in tRNA synthetase biology. Presentations showcase company’s progress in...
May 25, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA...
May 22, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference

Advancement in mechanistic understanding of efzofitimod’s modulation of myeloid cells to be featured in symposia presentation. Exposure-efficacy data from Phase 1b/2a study of efzofitimod support...
May 11, 2023 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA...
May 09, 2023 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with...
April 17, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting

SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
March 30, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases

SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
March 21, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution

Findings confirm LTBP1, a key regulator of TGF-β, as binding partner for tRNA synthetase DARS fragment ATYR0101 Data indicates ATYR0101 may have therapeutic potential for fibrotic pathologies...
March 20, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies

SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right